Author: USA Newsreport Online

Gabrielle (Gabby) Costigan appointed as BAE Systems Australia’s next Chief Executive Officer

Farnborough, UK, 29-Aug-2017 — /EuropaWire/ — Gabrielle (Gabby) Costigan, has been appointed as BAE Systems Australia’s next Chief Executive Officer, commencing with the Australian defence company on October 2, 2017 and assuming the role of CEO by March 2018 after a global transition program Ms Costigan was most recently CEO Asia, Linfox International

OSCE Mission to Moldova: Practical discussions on running an NGO during retreat held in Merenesti

Participants at the retreat engage in interactive activities while discussing co-operation among NGOs from both banks, Merenesti, 25 August 2017. (OSCE/Igor Schimbator) Photo details MOLDOVA, 29-Aug-2017 — /EuropaWire/ — On 25 August 2017, the OSCE Mission to Moldova supported a retreat for 28 representatives of NGOs from both banks of the Dniester/Nistru River

OSCE: Teachers from Moldovan vocational schools acquire skills to promote gender equality values in their work

Teachers from Moldovan vocational schools acquire skills to promote gender equality values in their work, Chisinau, 23 August 2017. (OSCE/Igor Schimbator) Photo details MOLDOVA, 29-Aug-2017 — /EuropaWire/ — Forty-six teachers from vocational schools throughout Moldova completed a Train the Trainer programme and learned new techniques for achieving gender equality and improving their skills in

EU Civil Protection Mechanism: European Commission helped mobilise firefighting aircraft for Italy to battle forest fires

BRUSSELS, 29-Aug-2017 — /EuropaWire/ — The Commission has helped mobilise firefighting aircraft for Italy, through the EU Civil Protection Mechanism, following another request by the country for assistance to battle forest fires. Responding immediately to the request, France has offered 3 planes (2 Canadairs and a reconnaissance aircraft). This is the third time Italy has received EU

Novartis: ACZ885 led to 15% reduction in the risk of major adverse cardiovascular events (MACE) compared to placebo

Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in addition to standard of care including lipid-lowering therapy Effect driven by 24% relative reduction in risk of heart attack; a non-significant 10% reduction

Novartis: ACZ885 reduced the rate of lung cancer incidence and mortality among study participants

Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is the first Phase III clinical trial to support a long-established hypothesis from pre-clinical models that inhibition of IL-1ß impacts cancer incidence and mortality  CANTOS